Comparing SG&A Expenses: Viatris Inc. vs Amicus Therapeutics, Inc. Trends and Insights

SG&A Expenses: Viatris vs Amicus - A Decade of Financial Insights

__timestampAmicus Therapeutics, Inc.Viatris Inc.
Wednesday, January 1, 2014207170001499100000
Thursday, January 1, 2015472690001923500000
Friday, January 1, 2016711510002351400000
Sunday, January 1, 2017886710002564000000
Monday, January 1, 20181272000002397300000
Tuesday, January 1, 20191698610002503400000
Wednesday, January 1, 20201564070003344600000
Friday, January 1, 20211927100004529200000
Saturday, January 1, 20222130410004179100000
Sunday, January 1, 20232752700004650100000
Loading chart...

Unleashing the power of data

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Amicus Therapeutics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Amicus Therapeutics in SG&A spending, with expenses peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, Amicus Therapeutics saw a more modest rise, with expenses growing by about 1,230% to reach $275 million in 2023. This disparity highlights Viatris's expansive operational scale compared to Amicus's more focused approach. Such insights are invaluable for investors and industry analysts seeking to understand the strategic priorities and market positioning of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025